Global Fintech Leaders Join Forces Behind Pollinate Platform
31.10.2019 14:17:00 EET | Business Wire | Press release
Pollinate, the business behind Tyl by NatWest, has launched with a growth capital investment round from a consortium of global industry leaders. Mastercard, Motive Partners and EFM Asset Management (EFM) will join RBS as both investors in, and partners to, the Pollinate business, which has raised a total of £60 million in funding to date.
Over the past decade, disruptive payment companies have challenged retail banks for ownership of their merchant relationships. Pollinate is reinventing merchant acquiring for banks, enabling them to compete effectively with these disruptors. The Pollinate technology is an innovative cloud-based platform that wraps around a bank’s legacy payment systems. The platform powers merchant and consumer digital experiences including onboarding, portals and loyalty programs, without costly and distracting platform migrations. This allows merchants to more effectively manage their businesses with digital tools and data integrations, grow their businesses by connecting with their consumers, and give back to their local communities. For banks, the Pollinate platform helps them understand and engage with their customers better and build stronger relationships with their merchants and consumers alike.
Conceived in 2017, the first deployment of the platform took place in Spring 2019 with the launch of the Tyl by NatWest merchant services business in the UK, and Pollinate is now in advanced discussions with other leading retail banks around the world.
Commenting on the announcement Alison Rose, Deputy CEO of NatWest Holdings and CEO of Commercial & Private Banking at RBS said, “I am hugely excited to announce the creation of a global merchant services company with Mastercard, Motive Partners and EFM Asset Management. Partnering with such high-quality companies, each of us bringing unique expertise and skills, allows for a truly international offering, benefitting not only our customers but the wider merchant acquiring space. We are committed to continually improving the products and experiences that we deliver to our customers, and the creation of Pollinate represents an innovative and successful approach of working with partners to do this.”
Jeff Emmanuel, Chief Investment Officer and Founder of EFM added: “As technology companies around the world are reimagining the delivery of financial services, a number of fintech ‘enablers’ have recognised the opportunity in bridging technological innovation, and the distribution scale and brand value of the largest financial institutions. Our disruptive fintech fund seeks opportunities through investment in dynamic companies which leverage their capabilities to deliver improved customer outcomes. Through combining machine learning with a unique ecosystem of data assets, Pollinate offers banks an exciting new service proposition for their customers. We are delighted to be backing this great team, and through our board participation, look forward to leveraging our network and experience in the space to maximise the opportunity.”
Pollinate is run by a team of executives from the Payments, Technology and Loyalty industries including Al Lukies CBE, Jonathan Hughes, Fiona Roach Canning, Tim Joslyn, David Beresford and Anna Moore.
Al Lukies, Pollinate CEO and Co-Founder said: “Retail banks around the world are facing common issues, but they remain the only ones in the payment chain who can connect directly with both merchants and consumers. They are therefore best placed to help SME’s process transactions, support their balance sheets, and grow their businesses, creating a virtuous circle between the bank, merchants, and consumers. As we know consumers increasingly expect a more personalised service from the businesses they interact with, regardless of their size, so at its heart Pollinate is about relationships and growth through connection - our platform enables relationships to be strengthened through fantastic digital experiences, and real-time data processing analytics and integrations.”
"Technology is making our everyday easier and more accessible. For small business owners, it's critical to separate the potential from the performance. That's why we're involved with Pollinate" said Ajay Banga, President and CEO of Mastercard. "Each of the partners brings its know-how, insights and technology to provide banks with real, tangible solutions that enables business owners to deliver the best customer experience."
Pollinate has secured important alliances with best in class brands across the payments and technology ecosystem. Available globally through the Azure cloud, the Pollinate platform utilises the best of Microsoft's big data and distributed AI platforms, threat Intelligence and authentication services to give banks and their customers access to compelling, intuitive services wherever they are. Other global partners of Pollinate, which include Mastercard, Endava, Motive Partners and EFM, ensures that Pollinate's banking clients, wherever they are based, can compete directly with the world's most innovative and disruptive companies.
“Our partner, Royal Bank of Scotland, has unique experience within the Merchant Services space and is perfectly positioned to roll out the Pollinate platform to small business across the United Kingdom. We are delighted to have a role alongside such an esteemed investor group, and we look forward to working with the Pollinate management team and our international ecosystem to building value for our partners, and ultimately SMEs and consumers.” - Rob Heyvaert, Managing Partner at Motive Partners.
ENDS
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191031005483/en/
Contact information
Media contacts
Nicky Harrison
FieldHouse Associates
pollinate@fieldhouseassociates.com
07739338842
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
